AMENDMENT NO. 1 TO EXCHANGE AGREEMENT
Exhibit 10.5
AMENDMENT NO. 1 TO
EXCHANGE AGREEMENT
This Amendment Number 1 (the Amendment) is made and entered into as of October 9, 2003, by and between Nektar Therapeutics, a Delaware corporation (the Company) and the entities set forth on Appendix I hereto (each a Holder and collectively the Holders).
RECITALS
Whereas, the Company and the Holders entered into an Exchange Agreement dated October 3, 2003 (the Agreement) pursuant to which the Holders shall exchange and cancel a portion of the Holders beneficial interest in the Companys 3.5% Convertible Subordinated Notes due 2007 (the Prior Notes) in consideration for the issuance by the Company to the Holders of the Companys 3% Convertible Subordinated Notes due 2010 (the New Notes) (the Exchange); and
Whereas, the Company and the Holders desire to enter into this Amendment to amend the Agreement.
AGREEMENT
Now, Therefore, in consideration of the mutual agreements, covenants and considerations contained herein, the receipt of which are hereby acknowledged, the undersigned hereby agree as follows:
1. Section 2.2. Section 2.2 is hereby amended, restated and replaced with the following:
(a) At the Closing, subject to the terms and conditions set forth herein, the Company shall issue and deliver to each Holder, against evidence of cancellation of such Holders beneficial interests in the Prior Notes, a note (the Note) in favor of such Holder, payable in the principal amount set forth opposite such Holders name in Appendix I.
(b) At the Closing, subject to the terms and conditions hereof, each Holder will cancel its beneficial interest in the Prior Notes and deliver to the Company evidence that the such beneficial interest has been cancelled on records maintained in book-entry form by The Depository Trust Company (DTC) and its participants.
2. Section 6.4. A new Section 6.4 shall be added to the Agreement as follows:
Section 6.4 The Depository Trust Company Eligibility. The Company covenants that it shall use its commercially reasonable efforts to cause the New Notes to be deposited with DTC and the Holders ownership to be reflected in book entry-form as soon as reasonably practicable in accordance with DTC policies and procedures, following the effective date of a registration statement covering the resale of the New Notes by the Holder.
3. Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be an original, and all of which shall constitute one instrument.
4. Full Force and Effect. The provisions of the Agreement shall remain in full force and effect, except as set forth herein.
2
In Witness Whereof, the parties hereto have executed this Amendment as of the date set forth in the first paragraph hereof.
COMPANY: | |||
|
| ||
Nektar Therapeutics | |||
|
| ||
Signature: |
| /s/ Ajit S. Gill |
|
| Ajit S. Gill | ||
| President, Chief Executive | ||
|
| ||
Address: | 150 Industrial Road | ||
| San Carlos, CA 94070 | ||
3
HOLDERS: | ||||||
| ||||||
Alexandra Global Master Fund Ltd. | ||||||
| ||||||
By: | Alexandra Investment Management, LLC, | |||||
| as Investment Advisor | |||||
| ||||||
| ||||||
Signature: |
| /s/ Dimitri Sogoloff |
| |||
|
| |||||
Print Name: |
| Dimitri Sogoloff |
| |||
|
| |||||
Title: | President |
| ||||
| ||||||
Address: | ||||||
| ||||||
c/o Alexandra Investment Management, LLC | ||||||
767 Third Avenue | ||||||
39th Floor | ||||||
New York, New York 10017 | ||||||
Facsimile No.: (212) 301-1810 | ||||||
4